Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus mepolizumab in relapsing or refractory EGPA
MOH_2022-07-21_010626Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Depemokimab + standard of care with Mepolizumab + standard of care (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
depemokimabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on MOH_2022-07-21_010626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-21_010626.